SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

AN2 Therapeutics Reports Third-Quarter 2026 Financial Results

AN2 Therapeutics reported financial results for the quarter ended September 30, 2026; the supplied text provides no financial figures.

ANTX
SquawkNews Desk 1 updates Updated Nov 09, 2026, 12:30 PM UTC

Story updates

12:30:47 PM UTC
SquawkNews
AN2 Therapeutics reported third-quarter 2026 financial results and pipeline updates. It has regulatory clearance for its global Phase 2 PV study, anticipates enrollment by year-end 2026, and selected AN2-504661 as a development candidate.Material DetailsContext by AI AnalystThis is an early-stage p…

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent busine…

Related stories

Nvidia Slides Premarket as Stock Futures Rally Nvidia shares fell sharply premarket after the company launched an investigation into CEO Jensen Huang. Dow Jones futures gained over 1.1%, while Treasury yields were largely stead M impact | EQUITY | Nov 09, 2026, 01:15 PM UTC Quanterix Q3 Revenue Rises 6.3% Sequentially M impact | EQUITY | Nov 09, 2026, 01:15 PM UTC Uniti Group Reports Q3 Revenue of $848.1 Million, Raises 2026 Outlook Uniti Group reported a third-quarter 2026 net loss of $244.5 million and adjusted EBITDA of $289.3 million. It raised 2026 revenue guidance to $3.665 billion-$3.695 billion. M impact | EQUITY | Nov 09, 2026, 01:15 PM UTC Delcath Systems Q3 Revenue Beats on Hepzato Growth M impact | EQUITY | Nov 09, 2026, 01:15 PM UTC ADC Therapeutics Reports Q3 Revenue of $21 Million, Runway Into 2029 ADC Therapeutics reported Q3 2026 net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million. It ended September with $189.2 millio M impact | EQUITY | Nov 09, 2026, 01:13 PM UTC OPAL Fuels Reports Q3 Revenue of $79.5 Million, Adjusted EBITDA of $26.7 Million Third-quarter revenue fell 5% year over year to $79.5 million, while net income was $1.7 million versus a $1.9 million loss. Adjusted EBITDA rose 32% to $26.7 million. OPAL maintai M impact | EQUITY | Nov 09, 2026, 01:13 PM UTC